| Patient | Elvis Presley |
|---|---|
| Date of birth | 1935-01-08 |
| Identifiers | MRN HR-ML003-SYN-TD; SSN (made up) 000-03-4417 |
| Document date | 1974-07-17 |
| Author | Rosalind Eberhardt-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Long-term prescription opioids and benzodiazepines from five prescribers, with fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, in a 39-year-old touring singer who wants to change how he takes his medicines. Please assess for substance use disorders and advise on medication for opioid use disorder and a safe benzodiazepine plan. [S]
Urgency: Within one week, on the day of his one-week primary care review, at his request before a Las Vegas engagement in five weeks. [S]
Questions for the consultant:
Mr. Presley, a 39-year-old singer, is seen at the request of Dr. Ashby-Nakagawa. He began opioids about five years ago for back and neck pain from performing, and benzodiazepines for sleep after late shows. Over time he took more than prescribed, found more than one prescriber, and felt sick and craved them when he ran short; a hospital stay some years ago withdrew him from opioids, and he restarted within months. He has never injected or used illicit drugs and does not drink. For the past week he has taken only this clinic's prescriptions. He last took hydromorphone about 18 hours ago and oxycodone about 20 hours ago, as planned, and is in mild to moderate withdrawal. He took diazepam and alprazolam last night. He has a Las Vegas engagement in five weeks and a tour after it and wants to start treatment now. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
10 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation | Up to five tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation | Up to three tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time | One tablet three times daily; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time | Up to three tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma | Stopped | Oral route | 1974-07-10 to 1974-07-10 | completed | S |
| Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist | One drop in each eye at bedtime | Ophthalmic route | 1974-07-10 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag | One spray for a suspected overdose; call 911 | Nasal route | 1974-07-10 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g in water once daily | Oral route | 1974-07-10 | active | S |
| Senna 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 1974-07-10 to 1974-08-07 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only | Two films once daily, or one film twice daily | Sublingual route | 1974-07-17 | active | S |
| Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable | One tablet four times daily; seven-day supply | Oral route | 1974-07-17 to 1974-08-07 | completed | S |
| Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1974-07-17 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | resolved | confirmed | R53.83 | S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses. |
| Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | E66.811 | S — Synthetic modern diagnosis anchored to his documented weight gain. |
| Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | H40.63X1 | S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes. |
| Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers | active | confirmed | F11.20 | S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis. |
| Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives | active | confirmed | F13.20 | S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis. |
| Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension. |
| Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP | active | confirmed | G47.33 | S — Synthetic modern diagnosis from a synthetic sleep study. |
| Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features | active | confirmed | K59.03 | S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon. |
Vital signs recorded on 1974-07-17; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Restless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C |
| Eyes | Pupils 5 mm and reactive; lacrimation |
| Skin | Piloerection; sweating; no injection marks |
| Neurological | Mild tremor of the outstretched hands; alert and oriented |
Data reviewed: Dr. Ashby-Nakagawa's intake note and the prescription drug monitoring program report (five prescribers, three pharmacies, about 145 MME a day with two benzodiazepines). DAST-10 7, AUDIT-C 0, PHQ-9 8, GAD-7 9. The structured safety assessment. Liver tests mildly raised; ECG normal with a QTc of 436 ms. In-laboratory polysomnography three days ago: apnea-hypopnea index 26 an hour, central apnea index 4. Point-of-care urine test today: hydromorphone, oxycodone and benzodiazepines; no fentanyl. COWS 12. [S]